The GWPRF chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the GWPRF chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The GWPRF stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View GWPRF Detailed Price Forecast - CNN Money||View GWPRF Detailed Summary - Google Finance|
|View GWPRF Detailed Summary - Yahoo! Finance||View GWPRF Stock Research & Analysis - Zacks.com|
|View GWPRF Trends & Analysis - Trade-Ideas||View GWPRF Major Holders - Barrons|
|View GWPRF Call Transcripts - NASDAQ||View GWPRF Breaking News & Analysis - Seeking Alpha|
|View GWPRF Annual Report - CompanySpotlight.com||View GWPRF OTC Short Report - OTCShortReport.com|
|View GWPRF Fundamentals - TradeKing||View GWPRF SEC Filings - Bar Chart|
|View Historical Prices for GWPRF - The WSJ||View Performance/Total Return for GWPRF - Morningstar|
|View the Analyst Estimates for GWPRF - MarketWatch||View the Earnings History for GWPRF - CNBC|
|View the GWPRF Earnings - StockMarketWatch||View GWPRF Buy or Sell Recommendations - MacroAxis|
|View the GWPRF Bullish Patterns - American Bulls||View GWPRF Short Pain Metrics - ShortPainBot.com|
|View GWPRF Stock Mentions - StockTwits||View GWPRF Stock Mentions - PennyStockTweets|
|View GWPRF Stock Mentions - Twitter||View GWPRF Investment Forum News - Investor Hub|
|View GWPRF Stock Mentions - Yahoo! Message Board||View GWPRF Stock Mentions - Seeking Alpha|
|View Insider Transactions for GWPRF - SECform4.com||View Insider Transactions for GWPRF - Insider Cow|
|View GWPRF Major Holdings Summary - CNBC||View Insider Disclosure for GWPRF - OTC Markets|
|View Insider Transactions for GWPRF - Yahoo! Finance||View Institutional Holdings for GWPRF - NASDAQ|
|View GWPRF Stock Insight & Charts - FinViz.com||View GWPRF Investment Charts - StockCharts.com|
|View GWPRF Stock Overview & Charts - BarChart||View GWPRF User Generated Charts - Trading View|
GW Pharma Analyst Expects $475M In Sales Of CBD Drug Expidiolex This Year
Posted on Thursday January 16, 2020
GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) exceeded fourth-quarter estimates for Epidiolex sales, notching $108 million in revenue for the CBD drug, according to the company's preliminary figures . The ...
Brace For Stricter FDA Regulation Of CBD Consumer Products, Analysts Say
Posted on Tuesday November 26, 2019
Cannabis stocks headed lower Tuesday after a Monday communication from the FDA, which sent warning letters to 13 companies for illegally selling products containing containing cannabidiol (CBD), violating the Federal Food, Drug, and Cosmetic Act. The 15 companies were warned for marketing CBD products for therapeutic uses in humans and/or animals as well as as dietary supplements. The FDA continues to maintain a strict stance on regulating the consumer CBD market, Bank of America Merrill Lynch analyst Christopher Carey said in his review of the dual communications from the FDA.
Analyst: New UK Cannabis Regulations Limit Usage, Call For Additional Research
Posted on Thursday November 14, 2019
New guidelines issued in the United Kingdom for the consumption and prescription of cannabis issued by the National Institute for Health Care and Excellence fell short of expectations, according to Cantor Fitzgerald. The guidelines are an example of the challenges that Canadian LPs and others could face in key European markets, analyst Pablo Zuanic said in a Tuesday note. This translates to only 8,000 to 9,000 patients out of a population of 500,000 who suffer from other types of epilepsy in the U.K., the analyst said.
UK Recommends NHS Reimburse GW Pharma's CBD-Based Epilepsy Drug
Posted on Tuesday November 12, 2019
GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) announced Sunday that two of its medicines have been recommended by the U.K.’s National Institute for Health and Care Excellence to receive routine reimbursement from the National Health Service. Epidiolex, known as Epidyolex in Europe, and Sativex were approved by the NHS for the treatment of epilepsy and multiple sclerosis, respectively. Doctors will be able to prescribe Epidyolex, an oral CBD solution, for children with two types of severe epilepsy, Lennox Gastaut syndrome and Dravet syndrome.